Malaria, HIV, Meningitis, and many other infectious diseases (IDs) are the leading cause of illness and death throughout the Developing World. Vigilant has been actively working on better diagnostic solutions for these disease states in partnership with leading international institutions. Sources >
Resource Rich Countries are also looking for better solutions for point of care treatment as costs escalate and faster, easier diagnostics are seen as a crucial step in better care. Vigilant is working on Flu A & B (link to NIH grant and paper+), Streptococcus, Clostridium difficile, and other areas like C Reactive Protein (link+) where regular testing can potentially lead to overall better understanding of a person’s general health.
Tested to be 8 times more sensitive than colorimetric measurements using current LFAs. VigilantDx is poised to offer the newest generation of nanotech enabled point-of-care diagnostics on the market – with virtually no change in sample preparation or testing protocol – in the near future.
VigilantDx’s patented Thermal Contrast Amplification (TCA) device combined with optimized Lateral Flow Immunoassay (LFA) test strips provides fast, quantitative, simple to use point-of-care information about a patient’s disease state.